Tasquinimod in the treatment of castrate-resistant prostate cancer – current status and future prospects
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Treatment options have significantly expanded in recent years for men with metastatic castration-resistant prostate cancer (mCRPC), with the routine use of immunotherapy (sipuleucel-T) and novel hormonal agents such as enzalutamide and abiraterone acetate prior to taxane-based chemotherapy or radium-223 radiotherapy. A number of immune checkpoints limit the immune response of the host to metastatic tumor progression in prostate cancer, one of which is an immunosuppressive and pro-angiogenic cell called the myeloid-derived suppressor cell (MDSC). Tasquinimod is a small molecular oral inhibitor of S100A9, a key cell surface regulator of MDSC function, and has shown anti-angiogenic, antitumor and immune-modulatory properties in preclinical models of prostate cancer and other solid tumors. A large randomized phase II trial of tasquinimod in men with chemotherapy-naïve mCRPC demonstrated a significant prolongation in radiographic and symptomatic progression-free survival compared with placebo, which was also associated with improvements in overall survival. Tasquinimod was studied in a global phase III randomized trial in men with bone mCRPC and, while it significantly improved radiographic progression-free survival, this did not result in an overall survival benefit. However, tasquinimod is under evaluation as well as a combination therapy with other systemic agents in prostate cancer and as a single agent in other solid tumors. This review encompasses the preclinical and clinical development of tasquinimod as a therapy for men with prostate cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, IL-2 has been used to expand effector T cells, but its systemic toxicity limits its clinical use (Mehta and Armstrong, 2016).”
From Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review (2026) · cites this paper as Mehta and Armstrong, 2016
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T., Chang, J., Markman, M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028 · cited 1×
“Targeting the androgen receptor axis has been classically known as an effective strategy in recurrent and metastatic prostate adenocarcinoma, and novel anti-neoplastic drugs have been developed and approved to target the androgen receptor as well, including enzalutamide and abiraterone [Beer et al. 2014; de Bono et al…”
BackgroundSelf-citationHaberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526 · cited 1×
“The Isaacs lab further explored this in prostate cancer cell lines (with 2% O2 conditions) in comparing deacetylation between controls to treatment separately with tasquinimod and with trichostatin A; this latter compound is a pan-class I/II HDAC inhibitor [Haberland et al. 2009].”
MethodScher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., et al. (2000) · Nature · doi:10.1038/35012626 · Cited by 1,217
Kelly, W. K., Halabi, S., Carducci, M., George, D., Mahoney, J. F., Stadler, W. M., Morris, M., Kantoff, P., Monk, J. P., Kaplan, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4767 · Cited by 483
Björk, P., Björk, A., Vogl, T., Stenström, M., Liberg, D., Olsson, A., Roth, J., Ivars, F., & Leanderson, T. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000097 · Cited by 356
Bunt, S. K., Clements, V. K., Hanson, E. M., Sinha, P., & Ostrand-Rosenberg, S. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0708446 · Cited by 277
Research works printed but not linked: 4
- Becker Y., 2006, Anticancer Res, 26, 1113
- Ichikawa T., 1992, Cancer Res, 52, 3022
- Isaacs J., 2012, Cancer Res, 73, 1
- Thoreson G., 2014, Can J Urol, 21, 98
Cited by
A S100A14-CCL2/CXCL5 signaling axis drives breast cancer metastasis
Li, X., Wang, M., Gong, T., Lei, X., Hu, T., Tian, M., Ding, F., Ma, F., Chen, H., & Liu, Z. (2020) · Theranostics · doi:10.7150/thno.42087 · Cited by 81
“Currently, inhibitors directly targeting S100B and S100A9 have been in clinical trials for melanoma and prostate cancer, respectively [48, 49].”
BackgroundDNA vaccines for prostate cancer
Zahm, C. D., Colluru, V. T., & McNeel, D. G. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.016 · Cited by 64
Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets
Szebeni, G. J., Vízler, C., Nagy, L. I., Kitajka, K., & Puskás, L. G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111958 · Cited by 61
“to prolong the progression-free survival of human castration-resistant prostate cancer patients [182].”
BackgroundMartori, C., Sánchez-Moral, L., Paul, T., Pardo, J. C., Pous, A. F., de Porras, V. R., & Sarrias, M. (2022) · Cancers · doi:10.3390/cancers14020440 · Cited by 53
Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX
Rea, D., Vecchio, V. D., Palma, G., Barbieri, A., Falco, M., Luciano, A., Biase, D. D., Perdonà, S., Facchini, G., & Arra, C. (2016) · BioMed Research International · doi:10.1155/2016/9750795 · Cited by 58
Metadata
- Authors
- Mehta, A. R., & Armstrong, A. J.
- Affiliations
- Duke Cancer Institute (US)
- Duke University (US)
- Corresponding author
- Armstrong, Andrew J.
- ORCID
- Armstrong, Andrew J.
- Venue
- Therapeutic Advances in Urology
- Publisher
- SAGE Publications
- Published
- 2015-09-16
- Volume
- 8
- Issue
- 1
- Pages
- 9-18
- ISSN
- 1756-2872 (ISSN-L)
- 1756-2880
- PMC
- PMC4707420
- OpenAlex
- W2219233634
- Cited by
- 41
- References
- 31
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 2 · 2019: 1 · 2017: 2 · 2016: 8
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Urology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- tasquinimod, castration-resistant prostate cancer, metastatic prostate cancer, myeloid-derived suppressor cells, immune checkpoint, anti-angiogenic therapy, progression-free survival, overall survival, combination therapy, bone metastasis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tasquinimod in the treatment of castrate-resistant prostate cancer – current status and future prospects. https://app.cochat.ai/papers/10.1177/1756287215603558
- The paper
- Mehta, A. R., & Armstrong, A. J. (2016). Tasquinimod in the treatment of castrate-resistant prostate cancer – current status and future prospects. Therapeutic Advances in Urology. https://doi.org/10.1177/1756287215603558
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.